• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, Q4 2010 - Product Image

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, Q4 2010

  • Published: December 2010
  • 98 pages
  • Global Markets Direct

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, Q4 2010

Summary

Global Markets Direct’s, “Chronic Kidney Disease (Chronic Renal Failure) Pipeline Review, Q4 2010”, provides an overview of the Chronic Kidney Disease (Chronic Renal Failure) therapeutic pipeline. This report provides information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure). “Chronic Kidney Disease (Chronic Renal Failure)-Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- A snapshot of the global therapeutic scenario for Chronic Kidney Disease (Chronic Renal Failure).
- A review of the Chronic Kidney READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Chronic Kidney Disease (Chronic Renal Failure) Overview
Therapeutics Development
An Overview of Pipeline Products for Chronic Kidney Disease (Chronic Renal Failure)
Chronic Kidney Disease (Chronic Renal Failure) Therapeutics under Development by Companies
Chronic Kidney Disease (Chronic Renal Failure) Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Companies Involved in Chronic Kidney Disease (Chronic Renal Failure) Therapeutics Development
Genzyme Corporation
Abbott Laboratories
United Therapeutics Corporation
Ash Access Technology, Inc.
Amgen Inc.
Eli Lilly and Company
Rockwell Medical Technologies, Inc.
Novartis AG
Astellas Pharma Inc.
Mitsubishi Tanabe Pharma Corporation
Pfizer Inc.
Cyclacel Pharmaceuticals Inc.
Regeneron Pharmaceuticals, Inc.
Dynavax Technologies Corporation
ProMetic Life Sciences Inc.
AplaGen GmbH
Proteon Therapeutics, Inc.
Reata Pharmaceuticals, Inc.
Thrasos, Inc.
Concert Pharmaceuticals, Inc.
CorMedix, Inc.
Vitae Pharmaceuticals, Inc.
Relypsa, Inc.
Endacea, Inc.
Vifor Pharma Ltd.
Sorbent Therapeutics, Inc.
InVasc Therapeutics, Inc.
Eurofarma
Varinel, Inc.
Iperboreal Pharma srl
Universities/Institutes Involved in Chronic Kidney Disease (Chronic Renal Failure) Therapeutics Development
Chronic Kidney Disease (Chronic Renal Failure) Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
AMG 223 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CellCept - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ferinject - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Genz-644470 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HEPLISAV - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Heptar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MP-146 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SBR759 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sulodexide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
YM533 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Zemplar (Abbott) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Zuragen - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Late Stage Drug Profiles – Universities/Institutes
ACE Inhibition - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Aldactone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Benazepril - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Benazepril + Valsartan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bisphosphonate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carvedilol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cholecalciferol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dextromethorphan + Silymarin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Erythropoietin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Everolimus - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Folate + Pyridoxine + Cyanocobalamin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hematide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Irbesartan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Iron-Sucrose - Drug Profile
Product Description
Mechanism of Action
R&D Progress
L-Carnitine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
N-acetylcysteine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nicobion + Cinacalcet - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Oral dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pentoxifylline - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Renagel + Cinacalcet - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rosiglitazone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sodium bicarbonate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Chronic Kidney Disease (Chronic Renal Failure) - Featured News
Nov 22, 2010: Reata And Abbott Announce Positive Phase IIb Chronic Kidney Disease Study Results For Bardoxolone Methyl
Nov 19, 2010: FibroGen To Present Phase IIa Results Of FG-4592 At American Society Of Nephrology Renal Week
Nov 11, 2010: Reata Pharmaceuticals To Present Data From Pivotal Phase IIb Trial In Type 2 Diabetics With Chronic Kidney Disease
Oct 25, 2010: Tengion Presents New Animal Data On Kidney Regeneration At American Society For Transplantation Annual Conference
Oct 18, 2010: Amgen To Review TREAT Results And Propose Updates To ESA Labeling For Chronic Renal Failure Patients At FDA Advisory Committee Meeting
Sep 29, 2010: Tengion Presents Data On Neo-Kidney Augment At International Society For Cellular Therapy
Sep 28, 2010: Dynavax Announces DSMB Clearance To Continue Two Phase III HEPLISAV Trials In CKD Patients
Sep 13, 2010: Tengion Announces Publication Of Preclinical Study In American Journal Of Physiology Renal Physiology
Jun 29, 2010: Vifor Pharma's PA21 Meets Primary And Secondary Endpoints In Phase II Study
Jun 25, 2010: CorMedix Initiates Phase II Clinical Trial Of CRMD-001 For Treatment Of Chronic Kidney Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos